ST. LOUIS, November 20, 2026 — Two studies published this month in the Journal of the American Medical Association have identified blood biomarkers that correlate with chronic traumatic encephalopathy, a disease that until now could only be confirmed after death. The findings mark the closest science has come to a blood test for CTE in living patients, though researchers caution that validation in larger, more diverse groups is still required before clinical use.
A Long Wait for Answers
For families of former athletes, military veterans, and survivors of domestic violence, the diagnosis has always arrived too late. CTE, a neurodegenerative disease linked to repeated head trauma, can only be definitively diagnosed through brain autopsy. The BU CTE Center has posthumously diagnosed the disease in more than 100 former NFL players. A study of donated brains found CTE in 99 percent of NFL players examined and 87 percent of all former football players studied.
The human side of those numbers is a long goodbye. Symptoms — mood changes, memory loss, behavioral shifts — often begin years or decades after the hits stop. Without a way to see the disease in a living brain, patients and clinicians have been left managing symptoms without a name for the cause.
What the New Studies Found
The Washington University School of Medicine study, published November 13, analyzed 229 participants across multiple neurodegenerative conditions. Researchers discovered that a protein fragment called eMTBR-tau243 — originally studied as an Alzheimer’s biomarker — was significantly elevated in 11 people with autopsy-confirmed CTE compared to healthy controls. Levels rose with disease severity. The test distinguished advanced CTE from healthy controls with an area under the curve of 0.96, indicating near-perfect accuracy for that stage.
The Boston University study, published the same week, examined 21 former football players who had donated blood before death and brain donation. Eighteen were found to have CTE, 16 with high-stage disease. In this group, plasma p-tau217 and neurofilament light chain (NfL) correlated with CTE pathology and years of play.
The Catch: Early Disease Remains Invisible
Both studies hit the same wall. The WashU test could not reliably identify early-stage CTE. The BU cohort was small and focused on advanced cases. Michael Alosco, co-director of clinical research at the BU CTE Center, called the findings a potential “game changer” but stressed the test appears effective only for advanced disease. Kanta Horie, PhD, co-senior author of the WashU study, noted that pharmaceutical companies are developing CTE therapies but lack biomarkers to identify patients and measure treatment response.
Current findings require confirmation in larger, diverse cohorts before any clinical diagnostic deployment. No validated blood test for CTE in living patients exists yet.
What This Means for Patients and Families
If validated, a blood test could change the landscape for at-risk groups: former contact-sport athletes, combat veterans, and domestic violence survivors. It would allow monitoring over time and, critically, enable clinical trials for treatments that currently have no way to measure efficacy. For families who have watched loved ones decline without answers, the possibility of a name — and a target — while there is still time to plan matters more than any statistic.
“We are potentially opening a new door for diagnosing and treating CTE in living patients,” Horie said. The next step is the validation studies that will determine whether that door stays open.
Sources
- New studies indicate possibility of detecting CTE through blood tests, paving way to test for disease in living patients
- Chronic traumatic encephalopathy
- Progress toward a blood test for CTE | WashU Medicine
- Blood Biomarker Shows Promise for Detecting Advanced Chronic Traumatic Encephalopathy
- Progress Toward a Blood Test for CTE | Newswise
- Scientists find blood biomarker that opens door to CTE diagnosis in living patients
Photo: LittleT889 (CC BY-SA 4.0)





